AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2711525 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed, permanently closed drainage system with maximum obtainable low pressure of 80% vacuum
Number of subjects: 0
Study 30510098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley manoeuvre
Number of subjects: 134
Study 30510098 — intervention group
Group type: COMPARATOR
Intervention: Sham manoeuvre
Number of subjects: 134
Study 29031763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment in SXB-15
Number of subjects: 437
Study 29031763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment in SXB-22
Number of subjects: 437
Study 25934164 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG20 (52-mg levonorgestrel intrauterine contraceptive)
Number of subjects: 1751
Study 23857972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus capecitabine (2,000 mg/m2)
Number of subjects: 442
Study 23857972 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy (2,500 mg/m2)
Number of subjects: 442
Study 22088587 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids of puerarin
Number of subjects: 67
Study 22088587 — intervention group
Group type: COMPARATOR
Intervention: Tanshinone II A sulfate
Number of subjects: 67
Study 18990499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hydrocortisone
Number of subjects: 84
Study 18990499 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg hydrocortisone
Number of subjects: 84
Study 18990499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17143357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg over 4 hours, every 12 hours for 3 doses
Number of subjects: 34
Study 17143357 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy alone
Number of subjects: 34
Study 17143357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 34
Study 14673697 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal absorption of estradiol in normal subjects
Number of subjects: 39
Study 14673697 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal absorption of estradiol in patients with polyneuropathy
Number of subjects: 39
Study 10871969 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin treatment at home
Number of subjects: 201
Study 10871969 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin treatment in hospital
Number of subjects: 201
Study 10871969 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 201
Study 9663831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 5 g
Number of subjects: 0
Study 9663831 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium 3.4 g
Number of subjects: 0
Study 9663831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose 2 g
Number of subjects: 0
Study 9663831 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 g
Number of subjects: 0
Study 8200722 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaprose (90 mg/day for 10 days)
Number of subjects: 20
Study 8200722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30349279 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC perindopril/amlodipine (5/5 mg, uptitrated to 10/10 mg every two weeks)
Number of subjects: 60
Study 30349279 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC perindopril/amlodipine
Number of subjects: 60
Study 27600155 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT to 66Gy in 3 fractions (one week)
Number of subjects: 102
Study 27600155 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT to 70Gy (7 weeks)
Number of subjects: 102
Study 24834887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg iodine load and 80 kV(p) tube voltage
Number of subjects: 136
Study 24834887 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg iodine load and 80 kV(p) tube voltage
Number of subjects: 136
Study 24834887 — intervention group
Group type: COMPARATOR
Intervention: 600 mg/kg iodine load and 120 kV(p) tube voltage
Number of subjects: 136
Study 24834887 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (400-80, 500-80, 600-120)
Number of subjects: 136
Study 22491963 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 10
Study 22491963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22491963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study 22491963 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 10
Study 20634736 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage with leucine (22.5 mg/kg, total 45 mg/kg)
Number of subjects: 20
Study 20634736 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate beverage without leucine (control)
Number of subjects: 20
Study 18576898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg plus misoprostol 200 microg twice/day for 14 days
Number of subjects: 19
Study 18576898 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg alone
Number of subjects: 19
Study 16022753 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (50 g)/guar gum (2.5 g) load with standard breakfast (GG)
Number of subjects: 58
Study 16022753 — intervention group
Group type: COMPARATOR
Intervention: Water (250 ml) with standard breakfast (W)
Number of subjects: 58
Study 12450328 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled prior frequency of occurrence
Number of subjects: 0
Study 12450328 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term priming
Number of subjects: 0
Study 12450328 — intervention group
Group type: EXPERIMENTAL
Intervention: Global memory model
Number of subjects: 0
Study 12450328 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-frequency effects
Number of subjects: 0
Study 10619535 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic treatment
Number of subjects: 381
Study 10619535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral premedication
Number of subjects: 381
Study 10619535 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-based procedures
Number of subjects: 381
Study 10619535 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety intervention (general)
Number of subjects: 381
Study 10619535 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 381
Study 8566676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan 3 gr/day
Number of subjects: 60
Study 8566676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan 4 gr/day
Number of subjects: 60
Study 8566676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1826823 — intervention group
Group type: COMPARATOR
Intervention: Abrasio only
Number of subjects: 292
Study 1826823 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxy progesterone acetate 500 mg i.m. twice weekly for 3 months
Number of subjects: 292
Study 7042372 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 9 mg (Celeston Chronodose)
Number of subjects: 24
Study 7042372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31049826 — intervention group
Group type: EXPERIMENTAL
Intervention: d3RP‐NF2
Number of subjects: 45
Study 31049826 — intervention group
Group type: COMPARATOR
Intervention: dHEP‐NF2
Number of subjects: 45
Study 29952137 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9
Study 29952137 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9
Study 29952137 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9
Study 29952137 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9
Study 27802950 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Navigator (FN) intervention with daily contact addressing informational and emotional communication needs.
Number of subjects: 26
Study 27802950 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Navigator (FN) intervention
Number of subjects: 26
Study 27802950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 24332392 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplugged curriculum
Number of subjects: 7079
Study 24332392 — intervention group
Group type: COMPARATOR
Intervention: Usual health education (control)
Number of subjects: 7079
Study 22145671 — intervention group
Group type: COMPARATOR
Intervention: MOVE programme
Number of subjects: 101
Study 22145671 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus MOVE programme
Number of subjects: 101
Study 22145671 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition counselling
Number of subjects: 101
Study 19149817 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day)
Number of subjects: 80
Study 19149817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride 0.5% (TetraVisc)
Number of subjects: 100
Study 17189801 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% jelly
Number of subjects: 100
Study 15159498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cholesterol subgroup (no-APOE epsilon4 allele)
Number of subjects: 443
Study 15159498 — intervention group
Group type: COMPARATOR
Intervention: Normal-cholesterol subgroups (with or without APOE epsilon4)
Number of subjects: 443
Study 12352474 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (ERY)
Number of subjects: 68
Study 12352474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 68
Study 9843526 — intervention group
Group type: EXPERIMENTAL
Intervention: Torso heating (THT)
Number of subjects: 6
Study 9843526 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CT) with Arctic mitts
Number of subjects: 6
Study 9843526 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CT)
Number of subjects: 6
Study 7865319 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Risk Assessment Battery (C-RAB)
Number of subjects: 0
Study 7865319 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil version of Risk Assessment Battery (RAB)
Number of subjects: 0
Study 2912011 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee at 58 degrees C (steaming hot)
Number of subjects: 0
Study 2912011 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee at 37 degrees C (warm)
Number of subjects: 0
Study 2912011 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee at 4 degrees C (ice cold)
Number of subjects: 0
Study 2912011 — intervention group
Group type: EXPERIMENTAL
Intervention: All temperatures of coffee (hot, warm, cold)
Number of subjects: 0
Study 5531862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol
Number of subjects: 0
Study 5531862 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine therapy
Number of subjects: 0
Study 5531862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol in a patient with a completely denervated hand
Number of subjects: 0
Study 31416745 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose minocycline (200 mg/day)
Number of subjects: 75
Study 31416745 — intervention group
Group type: COMPARATOR
Intervention: Low dose minocycline (100 mg/day)
Number of subjects: 75
Study 31416745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29259181 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules (2 g/day for 8 weeks)
Number of subjects: 106
Study 29259181 — intervention group
Group type: COMPARATOR
Intervention: Fresh fish (250 g twice weekly for 8 weeks)
Number of subjects: 106
Study 25780304 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Asc (2‐L polyethylene glycol with ascorbic acid 20 g)
Number of subjects: 226
Study 25780304 — intervention group
Group type: COMPARATOR
Intervention: 4‐L PEG
Number of subjects: 226
Study 24792591 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml iodinated contrast agent/100 kVp
Number of subjects: 120
Study 24792591 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml iodinated contrast agent/80 kVp
Number of subjects: 120
Study 24792591 — intervention group
Group type: COMPARATOR
Intervention: 70 ml iodinated contrast agent/120 kVp
Number of subjects: 120
Study 22632135 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational program for caregivers (10 sessions of 90 minutes over 5 weeks) + antipsychotic drug treatment for patients
Number of subjects: 70
Study 22632135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psycho-educational program)
Number of subjects: 70
Study 19253021 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitake liquid extract at 0.1, 0.5, 1.5, 3, or 5 mg/kg twice daily for 3 weeks
Number of subjects: 34
Study 17312364 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection ointment
Number of subjects: 0
Study 17312364 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care
Number of subjects: 0
Study 17312364 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective gloves
Number of subjects: 0
Study 17312364 — intervention group
Group type: COMPARATOR
Intervention: Skin protection
Number of subjects: 0
Study 17312364 — intervention group
Group type: COMPARATOR
Intervention: UV hardening
Number of subjects: 0
Study 17312364 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 16061595 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor Milk (DM)
Number of subjects: 243
Study 16061595 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm Formula (PF)
Number of subjects: 243
Study 16061595 — intervention group
Group type: COMPARATOR
Intervention: Mother's Milk (MM)
Number of subjects: 243
Study 12234565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LMWH for thromboprophylaxis for the first postoperative week
Number of subjects: 0
Study 12234565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin or enoxaparin for a further 3 weeks
Number of subjects: 0
Study 12234565 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with LMWH for at least one month
Number of subjects: 0
Study 10212537 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate or delayed-immediate implant placement techniques
Number of subjects: 143
Study 10212537 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants in the posterior region of the maxilla
Number of subjects: 143
Study 10212537 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters (bleeding, pocket depth, implant mobility)
Number of subjects: 143
Study 7530641 — intervention group
Group type: EXPERIMENTAL
Intervention: Real feedback (R-FB)
Number of subjects: 10
Study 7530641 — intervention group
Group type: COMPARATOR
Intervention: Dummy feedback (D-FB)
Number of subjects: 10
Study 7530641 — intervention group
Group type: COMPARATOR
Intervention: Perceptuomotor feedback (PM)
Number of subjects: 10
Study 7530641 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex task difficulty
Number of subjects: 10
Study 7530641 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple task difficulty
Number of subjects: 10
Study 2212968 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger blood pressure monitor (Marshall, Astro F‐88)
Number of subjects: 125
Study 2212968 — intervention group
Group type: COMPARATOR
Intervention: Brachial mercury sphygmomanometer
Number of subjects: 125
Study 508702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Fe dextran, 100 mg twice per week for 10-12 weeks
Number of subjects: 0
Study 508702 — intervention group
Group type: COMPARATOR
Intervention: Oral Fe, 120 mg/d, 6 d/week for 10-12 weeks
Number of subjects: 0
Study 508702 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Fe by total dose infusion of Fe dextran
Number of subjects: 0
Study 30256915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 4,000 IU/d
Number of subjects: 70
Study 30256915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2,000 IU/d
Number of subjects: 70
Study 30256915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30256915 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations
Number of subjects: 70
Study 29121356 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 mL cefazolin-lidocaine solution (0.3 mL cefazolin and 0.2 mL 2% lidocaine)
Number of subjects: 54
Study 29121356 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection of 0.5 mL cefazolin-balanced salt solution (0.3 mL cefazolin and 0.2 mL balanced salt solution)
Number of subjects: 54
Study 26384727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (active monitoring)
Number of subjects: 42
Study 23714599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance-moderate-endurance (Re)
Number of subjects: 100
Study 23714599 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-resistance-high-endurance (rE)
Number of subjects: 100
Study 23714599 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-resistance-moderate-endurance (re)
Number of subjects: 100
Study 23714599 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 21791109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal supportive care intervention 'Living with Prostate Cancer' combining self-management with tele-based group peer support
Number of subjects: 0
Study 21791109 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21791109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal supportive care intervention 'Living with Prostate Cancer'
Number of subjects: 0
Study 19185342 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 25928
Study 19185342 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 25928
Study 19185342 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 25928
Study 19185342 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 25928
Study 19185342 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 25928
Study 16461038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 3026
Study 16461038 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HDL cholesterol (continuous variable)
Number of subjects: 3026
Study 16461038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study 15265759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4))
Number of subjects: 32
Study 15265759 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study 10065696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 400 microg
Number of subjects: 12
Study 10065696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 400 microg plus oral activated charcoal
Number of subjects: 12
Study 10065696 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo plus oral activated charcoal
Number of subjects: 12
Study 7733034 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-protein diet with vitamin B-6 intakes of 0.5, 1.0, 1.5, and 2.0 mg/d
Number of subjects: 8
Study 7733034 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-protein diet with vitamin B-6 intakes of 0.5, 1.0, 1.5, and 2.0 mg/d
Number of subjects: 8
Study 2394068 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm vein infusion technique
Number of subjects: 46
Study 2394068 — intervention group
Group type: COMPARATOR
Intervention: Femoral vein infusion with single location dynamic scanning
Number of subjects: 46
Study 6153834 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 7
Study 31377905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg)
Number of subjects: 40
Study 31377905 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone implant (0.7 mg)
Number of subjects: 40
Study 31111752 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengji Yuhong ointment
Number of subjects: 400
Study 28632557 — intervention group
Group type: EXPERIMENTAL
Intervention: End-plate perforation
Number of subjects: 30
Study 28632557 — intervention group
Group type: COMPARATOR
Intervention: Control (no end-plate perforation)
Number of subjects: 30
Study 25336921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg)
Number of subjects: 54
Study 25336921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 54
Study 25336921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg) + Valsartan (160 mg)
Number of subjects: 54
Study 22631077 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical atrial incision aimed at decreasing the incidence of intraatrial reentrant tachycardia (IART)
Number of subjects: 29
Study 22631077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical atrial incision)
Number of subjects: 29
Study 22631077 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical atrial incision
Number of subjects: 29
Study 20448359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salvia miltiorrhiza and prednisolone
Number of subjects: 120
Study 20448359 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 120
Study 17505680 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication (NF)
Number of subjects: 14
Study 17505680 — intervention group
Group type: COMPARATOR
Intervention: Vertical gastric plication (VGP)
Number of subjects: 14
Study 15661417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (TAD) 20 mg on alternate days for 4 weeks
Number of subjects: 32
Study 15661417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) for 4 weeks
Number of subjects: 32